Prime Medicine
CompanyUnited States
Prime Medicine develops one asset, in phase 1 (PM577a in Wilson disease). Mostly gene editing acting on DNA repair and ATP7B; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1Prime editing therapy to correct the H1069Q mutation in ATP7B
Phase 1, Gene editing, DNA repair, ATP7B, Wilson disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Similar companies6